Skip to main content

Vipers’ Self-Defense Mechanism Could Spark a New Antivenom Strategy

Toxin-inhibiting proteins evolved by rattlesnakes protected mice from lethal venom doses and showed activity against toxins from some other vipers.

Written bySneha Khedkar
| 4 min read
A photograph of a rattlesnake against a jungle-like background.
Register for free to listen to this article
Listen with Speechify
0:00
4:00

Nearly a century ago, naturalists discovered something intriguing about some species of vipers and rattlesnakes: They are resistant to their own venom, and their serum protects experimental animals from lethal effects of the snakes’ toxins.1,2

A few years ago, researchers characterized the serum of such snakes and found proteins that inhibit venom toxins that drive tissue damage and hemorrhage.3 “Vipers [have] been working with these proteins for 50 million years to protect themselves,” said Sean Brendan Carroll, an evolutionary developmental biologist at the University of Maryland. “So, they're pretty impressive inhibitors.”

Taking a leaf out of the snakes’ book, Carroll and his team explored an approach to treat venomous snakebites using these toxin-blocking proteins that snakes evolved to protect themselves. They found that a cocktail of these proteins from a rattlesnake species neutralizes its own venom and that of other evolutionarily distant vipers.4 Their results, published in Proceedings of the National Academy of Sciences, offer a strategy to develop potent antivenoms against deadly snakebites.

Using a snake’s own toxin-inhibiting proteins for antivenom “is a promising strategy,” said Kartik Sunagar, a venom researcher and evolutionary biologist at the Indian Institute of Science, who was not involved in the study. “This paper is a good example of that strategy,” he added.

Continue reading below...

Like this story? Sign up for FREE Newsletter updates:

Latest science news storiesTopic-tailored resources and eventsCustomized newsletter content
Subscribe

Harnessing Snakes’ Natural Venom Resistance

Many venoms consist of metalloproteinases that drive tissue damage and hemorrhage. In the 1970s, researchers isolated a glycoprotein, Fetuin-A, from the serum of pit vipers, that could inhibit venom metalloproteinases.5 In 2022, Carroll and his team found that this protein family, which they called FEUTAs, was much bigger than previously thought. 6

The researchers wondered if these proteins could offer an alternative to current antivenoms, which require injecting animals with snake venom, isolating the serum, and obtaining antibodies from it. This process is also expensive and can often result in immune reactions to the foreign antibodies, so finding a new venom antidote could have many benefits.

In the current study, the researchers preincubated individual recombinant FETUA proteins with lethal doses of venom of Western Diamondback rattlesnake and injected the mixture into mice. While they observed that different proteins reduced hemorrhage to different extents, no single protein prevented death.

So, Carroll and his colleagues tested cocktails of these proteins and found that combining two FETUA proteins neutralized the venom’s lethality. Not only did all the mice survive, but they also had no overall envenomation symptoms.

“[This was] a big surprise…[because] venoms contain maybe 50 or more toxins belonging to 10 or a dozen families,” said Carroll. “So, we had no expectation that just…the metalloproteinase inhibitors could block the lethality of the venom.”

The researchers then dug deeper to investigate if FETUA protein combinations would act similarly on other rattlesnake species venoms. Similar assays with the venom of the Eastern Diamondback rattlesnake revealed that a cocktail of three proteins provided complete protection to the animals.

Rattlesnake Serum Proteins Recognize a Broad Spectrum of Venom Toxins

Encouraged by these results, “We said, ‘Okay, well, how far will this [protection] go?’” said Carroll. To find out, they tested the ability of rattlesnake FETUA proteins to inhibit metalloproteinases found in the venoms of four pit viper species, which are evolutionarily distant from Western Diamondback rattlesnakes. Both in vitro and in vivo experiments revealed that FETUAs from rattlesnakes recognized and inhibited proteins from evolutionarily distant pit vipers, even though some mice succumbed to the venom of one snake species.

“That’s probably telling you that the interfaces between the inhibitor and the toxins are pretty well conserved over time,” said Carroll. “That increases the potential utility of these proteins because it says they can recognize a broad spectrum of toxins from different species.”

According to Sunagar, while the method is novel, “The disadvantage is that it's only effective against snakes that produce that kind of venom.” He also noted that the researchers preincubated the FETUA proteins with snake venom before injecting the mixture into animals, which does not replicate an actual snakebite.

This is particularly relevant because some viper venoms trigger neutrophil extracellular trap formation, which blocks blood vessels, entrapping venom toxins at one site in the body.6 “So, your drug has to be good enough to clear and access these toxins to neutralize them,” explained Sunagar.

Overall, he said this is a “fascinating evolutionary [biology] story and preclinical proof of concept,” but more work needs to be done to take this to the clinical stage.

“This is still the research phase,” agreed Carroll, adding that their results are applicable only to some snake families. The researchers are also looking into a similar strategy for additional venom toxins. “So many of our medicines come from nature,” said Carroll. “I'm somewhat optimistic that this [is] nature finding us yet another good lead. Is it the full solution? Only research can tell, but it's a great lead because these are impressive toxin inhibitors.”

Add The Scientist as a preferred source on Google

Add The Scientist as a preferred Google source to see more of our trusted coverage.

Meet the Author

  • Sneha Khedkar

    Sneha Khedkar is an Assistant Editor at The Scientist. She has a Master’s degree in biochemistry, after which she studied the molecular mechanisms of skin stem cell migration during wound healing as a research fellow at the Institute for Stem Cell Science and Regenerative Medicine in Bangalore, India. She has previously written for Scientific American, New Scientist, and Knowable Magazine, among others.

    View Full Profile

Related Topics

You might also be interested in...
Loading Next Article...
You might also be interested in...
Loading Next Article...
November digest cover
November 2026

Chemistry Meets Arcade Combat in “Reaction Rumble” Game

Choose your fighter! Enter the arena as chemical elements and dole out moves inspired by real-world reactions in this educational browser-based game.

View this Issue
Thumbnail

Make It Local, Make It Last: The Evolution of mRNA Protein Replacement Therapy

Engineering Bispecific Antibodies Against Emerging Viruses

Engineering Bispecific Antibodies Against Emerging Viruses

innovative-research-horizontal-lock-inverted-rgb-900px-w-72ppi
Advancing Research With Humanized Mouse Models

Advancing Research with Next-Generation Humanized Mouse Models

bioxcell
3d illustration showing amyloid plaques in Alzheimer's disease

Best Practices for Blood-Based Amyloid Pathology Testing

fujirebio logo

Products

Abstract image of circles and concentric lines on a blue and pink background.

MX Analytical and Precision Balances: Effortless Weighing and Secure Data Handling

Mettler
3D multicolored conceptual image of antibody molecules

Premium BsAb: LC-MS-Assisted Bispecific Antibody Production with >98% Heterodimer Purity

WuXi Biologics
Abstract conceptual image of AI technology for medical science research.

Exploring a New Era of Pharmaceutical Innovation

A photograph of plastic fragments floating in water, symbolizing contamination from sample storage tubes.

LVL SAFE® 2D-Coded Tubes: The Perfect Tube for Your Sample

AutoGen